Search results
Results from the WOW.Com Content Network
The settlement allows Endo to opt for a lower, one-time payment of $200 million immediately upon its exit from bankruptcy. The settlement, which Endo previewed in a November court filing, resolves ...
Bankrupt drugmaker Endo International said on Wednesday the federal government's opposition to its bankruptcy sale threatened to undo nearly $600 million in settlements reached with states and ...
The company's Chapter 11 bankruptcy filing in the Southern District of New York showed assets and liabilities in the range of $1 billion to $10 billion. Endo files for bankruptcy as U.S. opioid ...
In 2022, Endo's stock fell below $1 as the company faced restructuring of its $8 billion of debt. On August 17, 2022 Endo International Plc filed for Chapter 11 bankruptcy protection after reaching a $6 billion deal with some of its creditors. [11]
The following is a list of the 21 largest civil settlements, reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2017, ordered by the size of the total civil settlement. Some of these matters also resolved criminal fines and penalties, listed in parentheses, but these amounts are not considered when ...
The DOJ appealed Purdue's bankruptcy settlement to the U.S. Supreme Court when nearly all other creditors wished to settle, and its opposition delayed Endo's proposal to sell itself to a group of ...
Reverse payment patent settlements, also known as "pay-for-delay" agreements, [1] are a type of agreement that has been used to settle pharmaceutical patent infringement litigation (or threatened litigation), in which the company that has brought the suit agrees to pay the company it sued. That is, the patent holder pays the alleged infringer ...
Endo International Plc filed for bankruptcy on Tuesday after reaching a $6 billion deal with some of its creditors, as the U.S. drugmaker seeks to settle thousands of lawsuits over its alleged ...